Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Cancer Survival And Symptom Trials May Be "Ideal Drug Package" - Pazdur

Executive Summary

Submission of one cancer survival trial and one symptom trial for approval of oncologic agents would be considered optimal by FDA, Oncologic Drug Products Division Director Richard Pazdur, MD, said.

You may also be interested in...

FDA Reviewing Cancer Trial Endpoints, Oncology Director Pazdur Tells ASCO

FDA's Division of Oncologic Drug Products will conduct an internal review of regulatory endpoints for cancer trials, division Director Richard Pazdur, MD, said May 13 during the American Society of Clinical Oncology annual meeting in San Francisco.

Maxamine Melanoma Liver Subset Needs More Focused Study - FDA Cmte.

Maxim would have to conduct a new, larger study focused solely on metastatic melanoma that has spread to the liver in order to support approval of Maxamine, FDA's Oncologic Drugs Advisory Committee suggested Dec. 13.

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts